CL2020003364A1 - Tratamiento antidiabético cardiovascular y renal seguro - Google Patents

Tratamiento antidiabético cardiovascular y renal seguro

Info

Publication number
CL2020003364A1
CL2020003364A1 CL2020003364A CL2020003364A CL2020003364A1 CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1 CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1
Authority
CL
Chile
Prior art keywords
renal
cardiovascular
safe
antidiabetic treatment
antidiabetic
Prior art date
Application number
CL2020003364A
Other languages
English (en)
Inventor
Eynatten Maximilian Von
Odd-Erik Johansen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020003364A1 publication Critical patent/CL2020003364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere al tratamiento antidiabético cardiovascular y renal seguro.
CL2020003364A 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro CL2020003364A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18184034 2018-07-17
EP18187272 2018-08-03
EP18197472 2018-09-28
EP18202843 2018-10-26
EP19177388 2019-05-29

Publications (1)

Publication Number Publication Date
CL2020003364A1 true CL2020003364A1 (es) 2021-07-02

Family

ID=67262338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003364A CL2020003364A1 (es) 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro

Country Status (12)

Country Link
US (3) US20200022985A1 (es)
EP (1) EP3823625A1 (es)
JP (2) JP2021530508A (es)
KR (1) KR20210035227A (es)
CN (1) CN112437666A (es)
AU (2) AU2019306036B2 (es)
BR (1) BR112020026164A2 (es)
CA (1) CA3103735A1 (es)
CL (1) CL2020003364A1 (es)
MX (1) MX2021000554A (es)
PH (1) PH12021550101A1 (es)
WO (1) WO2020016230A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CN101035536A (zh) 2004-10-08 2007-09-12 诺瓦提斯公司 有机化合物的组合
CA2612142A1 (en) 2005-07-01 2007-01-11 Merck & Co., Inc. Process for synthesizing a cetp inhibitor
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US20130303462A1 (en) * 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2014140284A1 (en) * 2013-03-15 2014-09-18 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
BR112018072401A2 (pt) * 2016-06-10 2019-02-19 Boehringer Ingelheim International Gmbh combinações de linagliptina e metformina

Also Published As

Publication number Publication date
EP3823625A1 (en) 2021-05-26
AU2019306036B2 (en) 2025-05-15
AU2025217272A1 (en) 2025-08-28
JP2021530508A (ja) 2021-11-11
BR112020026164A2 (pt) 2021-03-23
PH12021550101A1 (en) 2021-09-27
JP2024124413A (ja) 2024-09-12
KR20210035227A (ko) 2021-03-31
CA3103735A1 (en) 2020-01-23
CN112437666A (zh) 2021-03-02
WO2020016230A1 (en) 2020-01-23
US20240398817A1 (en) 2024-12-05
AU2019306036A1 (en) 2020-12-17
US20200022985A1 (en) 2020-01-23
US20220160717A1 (en) 2022-05-26
MX2021000554A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
MX377710B (es) Anticuerpos monoclonales contra bcma.
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
CL2020003414A1 (es) Tratamiento antidiabético cardiovascular seguro
CL2016002455A1 (es) Anticuerpos multiespecíficos.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
EA201591665A1 (ru) Оральные составы деферазирокса
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX2023006416A (es) Anticuerpos, usos y metodos.
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
MX374286B (es) Compuestos organolepticos novedosos.
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
CL2019000572A1 (es) Compuesto de imida y uso del mismo.
CL2020003364A1 (es) Tratamiento antidiabético cardiovascular y renal seguro
MX374569B (es) Compuestos organolépticos novedosos.
MX380297B (es) Compuestos organolépticos novedosos.
RU2015121640A (ru) Мост с компенсатором